UK considerations NHS and MHRA guidance The UK health authorities have clear positions on weight loss treatments: The NHS offers GLP-1 medications through specialist weight management services for eligible patients MHRA has approved Wegovy, Saxenda, and Mounjaro based on comprehensive safety and efficacy data No GLP-1 patch products have received MHRA approval as weight loss treatments The MHRA has issued warnings about misleading claims in weight loss supplements Cost and access in the UK The financial aspect is a significant consideration for many: NHS provision : Limited availability through specialist weight management services with strict eligibility criteria Private prescriptions : 150-300 monthly, depending on medication and provider Commercial patches : 12-70 monthly, depending on brand and quantity While patches appear less expensive, they lack evidence of effectiveness, making them poor value regardless of price

How Epithalon layers with other clusters is a clinical conversation, not a self-prescribed stack
The original epithalamin extract received approval in Russia specifically for menopause-related symptoms, suggesting relevance for women during hormonal transitions
Slinic delivers this care through a service regulated by the General Pharmaceutical Council (GPhC)
Antioxidants 12(4):817 Bhandari R et al (2021) The Nrf2 pathway in psychiatric disorders: pathophysiological role and potential targeting
Hurtado Andrade, MD, also suggested HRT might make it easier to shed pounds by improving sleep and other quality-of-life measures